- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, announced that Dr. William G. Gerber, a non-independent member of the company's board of directors, resigned from the board, effective as of May 1, 2007. His resignation restores compliance with NASDAQ Marketplace Rule 4350(c)(1), which requires a majority of members of the board of directors to be comprised of independent directors. The non-compliance resulted from the appointment of Dr. Heiner Dreismann, a non-independent director, to the company's board on October 31, 2006.
The board of directors now is comprised of five (5) directors, three (3) of whom are independent within the meaning of the applicable NASDAQ listing standards.
On May 10, 2007, Nanogen, Inc. received a Nasdaq Staff Deficiency Letter indicating that the Company did not comply with the requirement for continued listing set forth in NASDAQ Marketplace Rule 4350(c)(1). As of the date of this press release, the company is again in full compliance with Nasdaq Marketplace Rule 4350(c)(1).
About Nanogen, Inc.
Nanogenís advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChipģ electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogenís ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogenís Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
For more information, please click here
Robert Saltmarsh, Chief Financial Officer, 858-410-4600
Suzanne Clancy, Corporate Communications, 858-410-4688
Porter Novelli Life Sciences
Kim Richards, Media & Investor Relations, 619-849-5377
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
MIT mathematicians identify limits to heat flow at the nanoscale: New formula identifies limits to nanoscale heat transfer, may help optimize devices that convert heat to electricity November 25th, 2015
Physicists explain the unusual behavior of strongly disordered superconductors: Using a theory they developed previously, the scientists have linked superconducting carrier density with the quantum properties of a substance November 25th, 2015
Scientists 'see' detailed make-up of deadly toxin for the first time: Exciting advance provides hope for developing novel potential method of treating pneumococcal diseases such as bacterial pneumonia, meningitis and septicaemia November 25th, 2015
Production of Nanocapsules Containing Omega-3 Powder in Iran November 24th, 2015
National Space Society Welcomes Geoff Notkin As New NSS Governor August 26th, 2015